Companies: 48,874 Total Market Cap: 132456628851223.12

Pharma Mar, S.A.

BME-PHM
Healthcare Biotechnology
Rank #6927
Market Cap 1.60 B
Volume 40,285
Price 90.84
Change (%) 2.93%
Country or region Spain Spain

Pharma Mar, S.A.'s latest marketcap:

1.60 B

As of 05/20/2025, Pharma Mar, S.A.'s market capitalization has reached $1.60 B. According to our data, Pharma Mar, S.A. is the 6927th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 1.60 B
Revenue (ttm) 197.57 M
Net Income (ttm) 22.34 M
Shares Out 17.57 M
EPS (ttm) 0
Forward PE 24.49
Ex-Dividend Date 06/25/2025
Earnings Date 04/25/2025
Market Cap Chart
Data Updated: 05/20/2025

Pharma Mar, S.A.'s yearly market capitalization.

Pharma Mar, S.A. has seen its market value grow from €1.31 B to €1.42 B since 2020, representing a total increase of 8.13% and an annual compound growth rate (CAGR) of 1.80%.
Date Market Cap Change (%)
05/20/2025 €1.42 B -4.53%
12/31/2024 €1.39 B 88.09%
12/29/2023 €738.49 M -36.23%
12/30/2022 €1.16 B 12.13%
12/30/2021 €1.03 B -21.36%
12/31/2020 €1.31 B

Company Profile

About Pharma Mar, S.A.

Pharma Mar, S.A. is a biopharmaceutical company specializing in oncology treatments. The company operates globally, with a focus on research, development, production, and commercialization of bio-active principles for cancer therapy.

Business Segments

  • Oncology: Develops and markets treatments for various cancers.
  • RNA Interference: Focuses on gene expression reduction and silencing for therapeutic applications.

Key Products & Pipeline

  • Yondelis: Used for soft tissue sarcoma and ovarian cancer.
  • Aplidin: Treats relapsed/refractory multiple myeloma.
  • Zepzelca: Targets small cell lung cancer.
  • Ecubectedin (PM14): In Phase II trials for solid tumors and Phase I for soft tissue sarcoma & prostate cancer.
  • PM534 & PM54: Phase I trials for solid tumors.
  • SYL1801: Phase II trials for macular degeneration.
  • SYL116011: Preclinical studies for ocular allergies.
  • SYL A & B: Investigational studies for retinitis pigmentosa.

Operations & History

Pharma Mar, S.A. serves markets in Spain, Italy, Germany, Ireland, France, the EU, the United States, and internationally. Founded in 1986, the company is headquartered in Madrid, Spain.

Frequently Asked Questions

As of 05/20/2025, Pharma Mar, S.A. (including the parent company, if applicable) has an estimated market capitalization of $1.60 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Pharma Mar, S.A. global market capitalization ranking is approximately 6927 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Spain
Founded 1986
IPO Date n/a
Employees 500
CEO Jose Fernandez Sousa-Faro
Sector Healthcare
Industry Biotechnology
Address Avenida de los Reyes, 1
Madrid, 28770
Spain
Website https://www.pharmamar.com
People Also Watch
VRTX
440.66 2.93%
CSL Limited
157.08 2.93%
REGN
596.54 2.93%
KRX-207940
732.96 2.93%